ASP Isotopes (NASDAQ:ASPI – Free Report) had its price target reduced by HC Wainwright from $5.50 to $4.50 in a research report sent to investors on Wednesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for ASP Isotopes’ FY2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.08) EPS.
ASP Isotopes Price Performance
ASPI traded down $0.12 during midday trading on Wednesday, reaching $2.04. 464,563 shares of the company’s stock were exchanged, compared to its average volume of 815,041. The company has a debt-to-equity ratio of 1.70, a current ratio of 3.57 and a quick ratio of 3.57. The stock has a market capitalization of $105.60 million, a PE ratio of -3.85 and a beta of 5.16. The business’s 50-day moving average price is $3.23 and its 200 day moving average price is $3.52. ASP Isotopes has a 1-year low of $0.84 and a 1-year high of $5.67.
ASP Isotopes (NASDAQ:ASPI – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.84 million for the quarter. As a group, equities analysts anticipate that ASP Isotopes will post -0.11 EPS for the current fiscal year.
Insider Transactions at ASP Isotopes
Institutional Investors Weigh In On ASP Isotopes
A number of institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its holdings in ASP Isotopes by 5.7% in the second quarter. Renaissance Technologies LLC now owns 171,800 shares of the company’s stock valued at $526,000 after purchasing an additional 9,200 shares during the period. Rathbones Group PLC lifted its position in shares of ASP Isotopes by 27.5% during the second quarter. Rathbones Group PLC now owns 195,915 shares of the company’s stock worth $600,000 after purchasing an additional 42,243 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of ASP Isotopes during the second quarter worth $116,000. Fielder Capital Group LLC acquired a new position in shares of ASP Isotopes during the second quarter worth $55,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of ASP Isotopes during the second quarter worth $381,000. 16.80% of the stock is currently owned by hedge funds and other institutional investors.
ASP Isotopes Company Profile
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Further Reading
- Five stocks we like better than ASP Isotopes
- What Are the FAANG Stocks and Are They Good Investments?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Investing in Construction Stocks
- MarketBeat Week in Review – 8/5 – 8/9
- Best Stocks Under $5.00
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.